当前位置:主页 > 医学论文 > 肿瘤论文 >

ZKSCAN3在乳腺癌组织中的表达及其临床意义

发布时间:2019-03-18 13:34
【摘要】:目的:探讨ZKSCAN3(zinc finger with KRAB and SCAN domains 3)在乳腺癌组织中的表达及其临床意义。方法 :应用免疫组织化学法检测120例乳腺癌组织及60例癌旁组织中ZKSCAN3蛋白的表达,并分析其与患者临床病理参数和总生存率之间的关系。进一步应用实时荧光定量PCR法和蛋白质印迹法检测乳腺癌组织及其相应癌旁组织中ZKSCAN3 m RNA和蛋白的表达水平。结果:乳腺癌组织中ZKSCAN3蛋白的阳性表达率[74%(89/120)]高于相应的癌旁组织[37%(22/60)](P0.001)。ZKSCAN3蛋白的表达与乳腺癌患者肿块大小、淋巴结转移、分化程度和肿瘤分期相关(P值均0.05),ZKSCAN3阳性表达患者的总生存率明显低于阴性患者(P=0.040)。乳腺癌组织中ZKSCAN3 m RNA和蛋白的表达水平均高于癌旁组织(P值均0.01)。结论 :ZKSCAN3与乳腺癌的发生、进展及转移有关,可能是乳腺癌的促癌基因。
[Abstract]:Objective: to investigate the expression of ZKSCAN3 (zinc finger with KRAB and SCAN domains-3 in breast cancer and its clinical significance. Methods: immunohistochemical method was used to detect the expression of ZKSCAN3 protein in 120 cases of breast cancer and 60 cases of paracancerous tissue, and the relationship between the expression and clinicopathological parameters and overall survival rate was analyzed. Real-time fluorescence quantitative PCR and Western blot were used to detect the expression of ZKSCAN3 m RNA and protein in breast cancer tissues and their corresponding paracancerous tissues. Results: the positive expression rate of ZKSCAN3 protein in breast cancer [74% (89 / 120)] was higher than that in paracancerous tissue [37% (22 / 60)] (P0.001). The expression of ZKSCAN3 protein was associated with tumor size and lymph node metastasis in patients with breast cancer. The overall survival rate of patients with positive expression of ZKSCAN3 was significantly lower than that of patients with negative expression (P < 0. 040). The expression level of ZKSCAN3 m RNA and protein in breast cancer tissues was higher than that in adjacent tissues (P < 0 01). Conclusion: ZKSCAN3 is associated with the occurrence, progression and metastasis of breast cancer, and may be a prooncogene of breast cancer.
【作者单位】: 郑州大学第一附属医院肿瘤科;郑州大学第一附属医院乳腺外科;
【分类号】:R737.9


本文编号:2442911

资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/zlx/2442911.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户a2fd1***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com